October 31st, 2013
Prolonged Dual Antiplatelet Therapy May Not be Necessary for Second-Generation Drug-Eluting Stents
Larry Husten, PHD
The precise duration of dual antiplatelet therapy (DAPT) following implantation of a drug-eluting stent (DES) has been the subject of considerable controversy. On the one hand, prolonged therapy may help prevent late stent thrombosis, which was particularly evident in first generation DESs. On the other hand, the risk of stent thrombosis may have diminished in […]
October 22nd, 2012
Selections from Richard Lehman’s Literature Review: October 22nd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include favorable lipid-level trends in U.S. adults, an angiotensin receptor neprilysin inhibitor for patients with HF and preserved systolic ejection fraction, and a long-term safety comparison of the Zotarolimus-eluting and Sirolimus-eluting coronary stents.
April 3rd, 2011
2-Year Outcomes of the RESOLUTE All Comers Trial
Larry Husten, PHD
The Resolute zotarolimus-eluting stent (ZES) is now starting to demonstrate good long-term results. At an interventional featured clinical study session at the ACC in New Orleans and in a simultaneous publication in the Lancet, Sigmund Silber and colleagues presented the 2-year findings of the RESOLUTE All Comers trial comparing the ZES with the Xience V […]
NEJM Journal Watch — Recent Cardiology Articles- Transcatheter Valve Replacement for Severe Tricuspid Regurgitation
- Time in Blood Pressure Target Range and Outcomes in Hypertension: Real-World Data
- When to Start Anticoagulation After Ischemic Stroke in Patients with Atrial Fibrillation
- Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis
- Secondary Hypertension in Young Adults